Methotrexate-induced pancytopenia: clinical characteristics, medication errors, and outcomes in a tertiary care centre: a retrospective single-centre study
Rheumatology International · 2025
DOI: 10.1007/s00296-025-05989-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Rheumatology International, 2025. Verfasst von Harshwardhan Patil und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Mysuru, India. Hauptthemen laut MEDLINE: Methotrexate, Pancytopenia, Medication Errors, Antirheumatic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Themen: Medikationssicherheit
Abstract (Originalsprache)
Methotrexate (MTX) is a widely prescribed disease-modifying antirheumatic drug (DMARD) used at ≤ 25 mg/week in inflammatory conditions. Although effective, MTX-induced Pancytopenia remains a serious adverse event, often resulting from medication errors, idiosyncratic reactions, comorbidities, or polypharmacy. To comprehensively characterize methotrexate-induced Pancytopenia's clinical profile, risk factors, and outcomes. A retrospective analysis was conducted on patients diagnosed with MTX-induced Pancytopenia between 2015 and 2024. Pancytopenia was defined as WBC < 3,500/mm³, Hb < 11 g/dL, and platelets < 150,000/mm³; severe pancytopenia met more stringent thresholds (WBC < 2,000/mm³, Hb < 10 g/dL, platelets < 50,000/mm³). Among 50 patients (35 females, median age 59.5 years), 48 had rheumatoid arthritis and 2 had psoriasis. The median MTX dose was 10 mg/week. Common symptoms included generalized weakness (n = 47), fatigue (n = 42), fever (n = 37), oral ulcers (n = 31), bleeding (n = 11), and skin lesions (n = 10). Severe Pancytopenia occurred in 46% (n = 23) and was associated with significantly higher mortality (26.1% vs. 7.4%; p = 0.04). Medication errors were identified in 26 (52%) cases, mostly at the patient level (n = 23). Time-to-onset analysis revealed a bimodal distribution: early onset (1-4 weeks, median 2 weeks) in error cases, and delayed onset (6-12 months, median 8 months) in error-free patients. Severe Pancytopenia was more frequent in early-onset cases (61% vs. 29%; p = 0.02). Eight patients died despite intervention. MTX-induced Pancytopenia is frequently attributable to preventable errors. Early-phase vigilance, patient education, clear dosing instructions, and systemic safeguards are essential to reduce life-threatening toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Mysuru, India.
- Department of Clinical Immunology and Rheumatology, JSS Medical College, JSS Academy of Higher Education and Research, Mysuru, India. drshivaravi@gmail.com.
- Department of Clinical Immunology and Rheumatology, JSS Medical College, JSS Academy of Higher Education and Research, Mysuru, India.
Zitieren
APA
Patil, H., Prasad, S., Subramanian, R., Mamadapur, M., Nikhil, R., & Paul, A. A. (2025). Methotrexate-induced pancytopenia: clinical characteristics, medication errors, and outcomes in a tertiary care centre: a retrospective single-centre study. Rheumatology International. https://doi.org/10.1007/s00296-025-05989-y
Vancouver
Patil H, Prasad S, Subramanian R, Mamadapur M, Nikhil R, Paul AA. Methotrexate-induced pancytopenia: clinical characteristics, medication errors, and outcomes in a tertiary care centre: a retrospective single-centre study. Rheumatology International. 2025. doi:10.1007/s00296-025-05989-y
BibTeX
@article{Patil2025,
author = {Patil, Harshwardhan and Prasad, Shiva and Subramanian, Ramaswamy and Mamadapur, Mahabaleshwar and Nikhil, R and Paul, Acsah Annie},
title = {Methotrexate-induced pancytopenia: clinical characteristics, medication errors, and outcomes in a tertiary care centre: a retrospective single-centre study},
journal = {Rheumatology International},
year = {2025},
doi = {10.1007/s00296-025-05989-y}
}
EUVIMED